AKTS · Aktis Oncology, Inc.
$26.51
-0.18 (-0.67%)
At close · Aug 26
Market Cap
$1.44B
Shares
55.62M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$26.51
Open$26.60
Day$25.96–26.96
Available close range$15.19–32.23
Avg vol 30d276K
Short int3.4M · 6.2% float · 15.0d
Short vol55%
DataJan 2026–Aug 2026
Filing10-Q · Aug 13
The closing range uses available history since Jan 9, 2026; less than a full year is stored.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
+4%
above
RSI (14)
61
neutral
MACD trend
Positive
52-week position
66%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+18%
trailing
6-month return
+29%
trailing
Relative strength
+17%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+64% holders QoQ · +52 funds added
Insider flow
Distributing
Net -$3.0M over 90 days · 100% sells
Short interest
Falling
6.20% of float · ▼ -0.7% MoM · 15.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
113 holders — 13F breadth
Squeeze score
66
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−32%
past year
ATR
5.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
+4%
Bullish
RSI (14)
61
Neutral
MACD trend
Positive
Bullish
52-week position
66%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+64% holders QoQ · +52 funds added
Insider flow
Distributing
Net -$3.0M over 90 days · 100% sells
Short interest
Falling
6.20% of float · ▼ -0.7% MoM · 15.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
113 holders — 13F breadth
Price context
position in its available closing range
Range low $15
Now $27 · 66%
Range high $32
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AKTS
this stock
Aktis Oncology, Inc.
|
$1.44B | — | — | — | 6.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AKTS | +6.0% | +18.4% | +29.1% | +20.1% | — |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +6.4% | +13.4% | +16.6% | +17.6% | — |
Key facts
CIK
2035832
CUSIP
01021M104
13F (30d)
101 filings
101 filers
Visit website
Investor relations